Xeris Biopharma Holdings, Inc. is a cutting-edge biopharmaceutical company operating out of Illinois. The company has made a name for itself by creating, developing, and selling innovative therapies that help patients suffering from a variety of conditions. Among the products in the company's catalog are Gvoke, a liquid-glucagon designed to alleviate severe hypoglycemia, Keveyis, a therapy that treats a range of primary periodic paralysis-related conditions, and Recorlev, a cortisol synthesis inhibitor for adult patients with Cushing's syndrome. Xeris Biopharma Holdings, Inc. has even more good news on the horizon, as it is pursuing a pipeline of development programs that will expand its already impressive array of products and take advantage of its proprietary formulation technology platforms, XeriSol and XeriJect. The company was founded in 2005 and headquartered in the bustling city of Chicago.
Xeris Biopharma Holdings Inc's ticker is XERS
The company's shares trade on the NASDAQ stock exchange
They are based in Chicago, Illinois
There are 51-200 employees working at Xeris Biopharma Holdings Inc
It is xerispharma.com
Xeris Biopharma Holdings Inc is in the Healthcare sector
Xeris Biopharma Holdings Inc is in the Biotechnology industry
The following five companies are Xeris Biopharma Holdings Inc's industry peers: